Drug Profile
RO 0506997
Alternative Names: A4I antagonist; RO0506997Latest Information Update: 18 Feb 2014
Price :
$50
*
At a glance
- Originator Roche
- Class
- Mechanism of Action Integrin alpha4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 01 Jan 2008 Discontinued - Phase-II for Multiple sclerosis in Spain (PO)
- 01 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in Spain (PO)
- 24 Mar 2005 Phase-II clinical trials in Rheumatoid arthritis in Spain (PO)